文献速递血脂与心血管预防

双重抗血小板治疗在卒中二级预防中的疗效与安全性:随机对照试验的系统评价与Meta分析

Efficacy and Safety of Using Dual Versus Monotherapy Antiplatelet Agents in Secondary Stroke Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
PubMed 文献 · Circulation · 2021-04-30

该系统评价与Meta分析纳入27 358例患者,比较双重抗血小板治疗(DAPT)与单药治疗在卒中或短暂性脑缺血发作二级预防中的疗效与安全性。结果显示DAPT降低复发性卒中风险(RR 0.71,95%CI 0.63-0.81)和复合结局风险(RR 0.76,95%CI 0.69-0.83),但增加大出血风险(RR 2.17,95%CI 1.45-3.25);亚组分析显示≤30天DAPT增加出血风险(RR 1.94,95%CI 1.08-3.52),但排除阿司匹林联合替格瑞洛后出血风险与单药治疗相当(RR 1.42,95%CI 0.77-2.60)。

要点

  • DAPT较单药治疗降低复发性卒中及复合终点风险,但增加大出血风险。
  • ≤30天DAPT增加出血风险,排除阿司匹林联合替格瑞洛后出血风险与单药相当。
  • 亚组和敏感性分析中DAPT降低卒中复发和复合结局的风险仍持续存在。

核心结论

  • 与单药治疗相比,DAPT降低复发性卒中和复合事件风险,但增加大出血风险,除非治疗限制在30天内且不包含阿司匹林联合替格瑞洛。

研究设计与样本

  • 系统评价与Meta分析,纳入比较DAPT与单药治疗用于复发性卒中或短暂性脑缺血发作二级预防的主要随机对照试验,共27 358例患者。

主要发现

  • DAPT降低复发性卒中风险(RR 0.71,95%CI 0.63-0.81)和复合结局风险(RR 0.76,95%CI 0.69-0.83)。
  • DAPT增加大出血风险(RR 2.17,95%CI 1.45-3.25)。
  • 亚组分析中≤30天DAPT增加出血风险(RR 1.94,95%CI 1.08-3.52)。
  • 敏感性分析排除阿司匹林联合替格瑞洛后,≤30天DAPT出血风险与单药治疗相当(RR 1.42,95%CI 0.77-2.60)。
  • 亚组和敏感性分析中DAPT降低卒中复发和复合结局的风险仍持续存在。

关键数值与推荐

  • 主要结局为卒中以及卒中、短暂性脑缺血发作、急性冠脉综合征和全因死亡的复合终点。
  • 安全结局为大出血。
  • 证据质量中至低,所有比较的异质性低(I2≤25%)。

临床怎么用

  • 对于非心源性栓塞性轻型卒中后的二级预防,可考虑限时使用DAPT以降低复发风险,但需权衡大出血风险。
  • 若采用≤30天DAPT,应避免阿司匹林联合替格瑞洛方案以减少出血风险。

局限性

  • 证据质量为中至低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dual antiplatelet treatment (DAPT) with aspirin plus clopidogrel for a limited time is recommended after minor noncardioembolic stroke. METHODS: We performed a meta-analysis of all major studies that compared the efficacy and safety of DAPT versus monotherapy for the secondary prevention of recurrent stroke or transient ischemic attack. The primary outcomes were stroke and the composite of stroke, transient ischemic attack, acute coronary syndrome, and death from any cause. The safety outcome was major hemorrhage. Relative risk (RR) and 95% CIs were calculated. Heterogeneity was assessed by I2 and Cochrane Q statistics. RESULTS: The analysis included 27 358 patients, the quality of evidence was moderate to low, and the heterogeneity for all the comparisons was low (I2≤25%). Compared with monotherapy, DAPT reduced the risk of recurrent stroke (RR, 0.71 [95% CI, 0.63-0.81]) and composite outcome (RR, 0.76 [95% CI, 0.69-0.83]) but increased the risk of major bleeding (RR, 2.17 [95% CI, 1.45-3.25]). In the subgroup analysis, ≤30 days of DAPT increased the risk of hemorrhage relative to monotherapy (RR, 1.94 [95% CI, 1.08-3.52]). In the sensitivity analysis, the risk for hemorrhage with ≤30 days of DAPT after excluding the combination of aspirin plus ticagrelor was comparable to monotherapy (RR, 1.42 [95% CI, 0.77-2.60]). However, the risk for stroke recurrence and composite outcomes in the subgroup and sensitivity analyses remain decreased compared with monotherapy. CONCLUSIONS: DAPT decreases the risk of recurrent stroke and composite events compared with monotherapy. DAPT increases the risk of major hemorrhage, except if the treatment is limited to 30 days and does not include the combination of aspirin plus ticagrelor.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Trifan G, Gorelick PB, Testai FD, et al. Efficacy and Safety of Using Dual Versus Monotherapy Antiplatelet Agents in Secondary Stroke Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. Circulation. 2021. PMID: 33926204. doi:10.1161/CIRCULATIONAHA.121.053782

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。